Meropenem

• Description :

  Meropenem (SM 7338) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL) [1][2].

• Product Name Alternative :

  SM 7338

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319

• Target :

  Antibiotic; Bacterial; Penicillin-binding protein (PBP)

• Type :

  Natural Products

• Related Pathways :

  Anti-infection

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Infection; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/meropenem.html

• Concentration :

  10mM

• Purity :

  99.85

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C(N12)=C(S[C@@H]3CN[C@H](C(N(C)C)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O

• Molecular Formula :

  C17H25N3O5S

• Molecular Weight :

  383.46

• Precautions :

  H315, H319

• References & Citations :

  [1]L Slaney, et al. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6.|[2]George G Zhanel, et al. Comparative review of the carbapenems. Drugs. 2007;67 (7) :1027-52.|[3]Umit Ateskan, et al. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27 (3) :247-52.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Natural Products

• Clinical Information :

  Launched

• Isoform :

  β-lactam

• Citation 01 :

  Biomed Pharmacother. 2023 Dec 31:169:115856.|Bioorg Chem. 2025 Jun 1:159:108421.|BMC Microbiol. 2025 Apr 29;25 (1) :257.|Diagn Microbiol Infect Dis. 2025 Nov 4;114 (2) :117181.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|Eur J Clin Microbiol Infect Dis. 2025 Sep 29.|Infect Drug Resist. 2021 Jun 30;14:2499-2507.|Infect Genet Evol. 2025 Sep:133:105780.|Int J Antimicrob Agents. 2025 Jun 9:107551.|J Antimicrob Chemother. 2020 Jul 1;75 (7) :1850-1858.|J Antimicrob Chemother. 2025 Nov 5:dkaf408.|J Glob Antimicrob Resist. 2025 Jun:43:198-202.|Microbiol Spectr. 2024 Aug 6;12 (8) :e0397923.|Microbiol Spectr. 2025 Oct 16:e0160325.|Microorganisms. 2024 Mar 13;12 (3) :575.|mLife. 2025 Apr 15;4 (2) :155-168.|Nano Today. 2024 Dec.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Nat Microbiol. 2023 Mar;8 (3) :410-423.|Open Forum Infect Dis. 2023 Jan 27;10 (2) :ofad038.|Proc Natl Acad Sci U S A. 2024 Jan 16;121 (3) :e2314514121.|Spectrochim Acta A Mol Biomol Spectrosc. 2020 Apr 5;230:118066.|Antimicrob Agents Chemother. 2018 Jul 27;62 (8) . pii: e00414-18. |bioRxiv. 2024 May 10.|Int J Antimicrob Agents. 2018 Aug;52 (2) :269-271.|iScience. 2025 Mar 28;28 (5) :112311.

• CAS Number :

  [96036-03-2]